Syros Pharmaceuticals Inc to Announce Update on Selective CDK7 Inhibitor Portfolio Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Syros Pharmaceuticals' conference call. (Operator Instructions) I would now like to hand the conference over to your speaker today, Naomi Aoki, VP of Corporate Communications and Investor Relations. Please go ahead, ma'am.
Thank you. This morning, we issued a press release providing an update on our portfolio of selection CDK7 inhibitors. This release, as well as the slides that we'll be reviewing on today's call, is available on the Investors and Media section of Syros' website at www.syros.com.
We will begin today's call with prepared remarks by Dr. Nancy Simonian, our Chief Executive Officer; and Dr. David Roth, our Chief Medical Officer. Then we will open the call for questions.
Dr. Eric Olson, our Chief Scientific Officer; Dr. Jeremy Springhorn, our Chief Business Officer; and Joe Ferra, our Chief Financial Officer, are also on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
